Clinical trials: Chronic Obstruct Airways Disease
Chronic Obstructive Pulmonary Disease
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
The objectives of the proposed study are to investigate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and prliminary efficacy of XH-S004 in moderate to severe COPD patients with a stale standards of care…
- Trial name
- NCT07035652
- Testing
- XH-S004 20 mg, 40 mg or 60 mg
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
COPD
A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPD
The aim of this clinical trial to determine the safety and effectiveness of treating the COPD symptoms with subcutaneous BOTOX injections in participants with moderate COPD.
- Trial name
- NCT06003049
- Testing
- OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- RMW Testing
Chronic Obstructive Pulmonary Disease (COPD)
Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
- Trial name
- NCT01425814
- Testing
- LAS100977, Reference
- Where
- 8 sites in Germany
- Volunteers
- 87 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
IMD-1041 Chronic Obstructive Pulmonary Disease: Proof of Concept (POC) Study
COPD is a lung disease in which the lung is damaged, making it hard to breathe. In COPD, the airways/tubes that carry air in and out of the lungs are partly obstructed, making it difficult to get air in and out.
- Trial name
- COPD (NCT00883584)
- Testing
- IMD-1041
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Institute of Medicinal Molecular Design, Inc.
COPD
A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device
Evaluate subjects in an prospective observational study Subjects will be administered scientifically validated questionnaires Evaluate Quality Improvement and Oxygen Utilization Improvements. 1.
- Trial name
- BRVB-OCD (NCT02627599)
- Testing
- Breath Responsive Variable Bolus Oxygen Conserving Device
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- StratiHealth
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in…
- Trial name
- NCT02006732
- Testing
- olodaterol, tiotropium
- Where
- 78 sites in United States, Australia and 9 more
- Volunteers
- 809 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Helium-3 MRI Imaging Study in COPD
This protocol describes the investigation of the use of hyperpolarised helium magnetic resonance imaging (MRI) in reflecting the regional differences in lung function of moderate to severe Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT02207452
- Testing
- He-3 MRI, Salbutamol, Ipratropium
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease
ASTUTE is a pragmatic open randomised 12-week multinational trial to evaluate the effectiveness of aclidinium bromide/formoterol fumarate dihydrate fixed-dose combination compared to standard of care bronchodilators in chronic…
- Trial name
- ASTUTE (NCT03181880)
- Testing
- Aclidinium bromide/formoterol fumarate combination, Standard of Care
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study to investigate the effect of 14-day treatment with BIIL 284 BS on sputum neutrophils and specific inflammatory markers in patients with clinically well-defined moderate chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02249338
- Testing
- BIIL 284 BS
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of the study is to identify demographic and non-spirometric clinical features predictive of the asthma-COPD overlap population.
- Trial name
- NCT02302417
- Testing
- Spirometry, ACOS clinical questionnaire
- Where
- 42 sites in United States, Argentina and 3 more
- Volunteers
- 1,215 people
- Sponsor
- GlaxoSmithKline
Pulmonary Emphysema
US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation
The purpose of this study is to determine whether the Aeris Bronchoscopic Lung Volume Reduction (BLVR) System is safe in patients with advanced emphysema.
- Trial name
- NCT00085852
- Testing
- BLVR
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)
The objective of this study is to assess the efficacy and safety of 12 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the Respimat inhaler) compared with tiotropium and placebo in…
- Trial name
- NCT01964352
- Testing
- tiotropium, olodaterol
- Where
- 77 sites in United States, Belgium and 8 more
- Volunteers
- 813 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Re-usable Respimat® Soft MistTM Inhaler Study
The study is to assess patient satisfaction with the inhaler attributes of the re-usable Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who are Respimat SMI-experienced and Respimat…
- Trial name
- NCT04011735
- Testing
- Respimat
- Where
- 20 sites in Belgium, Denmark and 4 more
- Volunteers
- 262 people
- Sponsor
- Boehringer Ingelheim
Emphysema, Chronic Obstructive Pulmonary Disease (COPD)
AeriSeal System for Lung Volume Reduction
The purpose of this study is to evaluate the safety and efficacy of AeriSeal treatment in patients with advanced emphysema.
- Conditions
- Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Emphysema, Lung Diseases
- Trial name
- NCT01051258
- Testing
- AeriSeal System
- Where
- 8 sites in Austria, France and 2 more
- Volunteers
- 55 people
- Sponsor
- Aeris Therapeutics
Pulmonary Disease, Chronic Obstructive
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
- Trial name
- NCT02850978
- Testing
- Spiolto
- Where
- Japan
- Volunteers
- 1,335 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease
The objective of this study is to compare the bronchodilator efficacy and safety of tiotropium inhalation capsule (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg q.i.d.) in patients with chronic obstructive pulmonary…
- Trial name
- NCT02172443
- Testing
- tiotropium inhalation powder capsules, Atrovent
- Volunteers
- 50 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
- Trial name
- NCT02182635
- Testing
- Ba253BINEB
- Volunteers
- 74 people
- Sponsor
- Boehringer Ingelheim
Asthma, Chronic Obstructive Pulmonary Disease
Outcome Study Following Reimbursement Changes in the Use of Fixed Combination Inhalers in Patients With Asthma or Chronic Obstructive Pulmonary Disease
To investigate how a switch from fixed combination treatment (ICS and LABA) to other treatments influence asthma or COPD treatment failure
- Trial name
- NCT01369810
- Where
- Sweden
- Volunteers
- 20,000 people
- Sponsor
- AstraZeneca
Sleep Apnea, Obstructive, Chronic Obstructive Pulmonary Disease
SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS
This is a prospective multipart clinical performance study to compare the ability of the SnoreSounds algorithm with polysomnography (PSG) and a type III Home Sleep Testing (HST) device to identify patients with obstructive sleep…
- Trial name
- SNORESOUNDS (NCT03288376)
- Where
- 3 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Incyphae, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.